Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study.

Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study.

<p><strong>Objectives:</strong> Recruitment to pragmatic trials is often difficult, and little is known about factors associated with key participation and treatment decisions. These were explored in the Prostate cancer testing and Treatment (ProtecT) study.</p> <...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Donovan, JL, Opmeer, B, Young, GJ, Mills, N, Martin, RM, Lane, JA, Metcalfe, C, Peters, TJ, Davis, M, Turner, EL, Walsh, E, Neal, DE, Hamdy, FC, ProtecT Study Group
Format:	Journal article
Język:	English
Wydane:	Elsevier 2019

Podobne zapisy

A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial
od: Donovan, JL, i wsp.
Wydane: (2017)

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
od: J. Donovan, i wsp.
Wydane: (2003-01-01)

Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study
od: Young, GJ, i wsp.
Wydane: (2017)

Addressing patient treatment preferences at trial recruitment.
od: Mills, N, i wsp.
Wydane: (2011)

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
od: Lane, A, i wsp.
Wydane: (2016)

Exploring treatment preferences facilitated recruitment to randomized controlled trials
od: Mills, N, i wsp.
Wydane: (2011)

Exploring treatment preferences facilitated recruitment to randomized controlled trials.
od: Mills, N, i wsp.
Wydane: (2011)

Factors distinguishing general practitioners who more readily participated in a large randomized trial were identified.
od: Down, L, i wsp.
Wydane: (2009)

Addressing patient treatment preferences at trial recruitment
od: Mills Nicola, i wsp.
Wydane: (2011-12-01)

Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study).
od: Donovan, J, i wsp.
Wydane: (2003)

Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen
od: Harrison, S, i wsp.
Wydane: (2020)

The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation
od: Rooshenas, L, i wsp.
Wydane: (2018)

A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study).
od: Mills, N, i wsp.
Wydane: (2006)

Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study).
od: Turner, E, i wsp.
Wydane: (2011)

Radiotherapy for prostate cancer: is it 'what you do' or 'the way that you do it'? A UK perspective on technique and quality assurance.
od: Mason, MD, i wsp.
Wydane: (2016)

Low risk research using routinely collected identifiable health information without informed consent: encounters with the Patient Information Advisory Group.
od: Metcalfe, C, i wsp.
Wydane: (2008)

Informed consent in randomised controlled trials: development and preliminary evaluation of a measure of participatory and informed consent (PIC)
od: Wade, J, i wsp.
Wydane: (2017)

Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial.
od: Walsh, E, i wsp.
Wydane: (2016)

Experiences and decision processes during PSA testing and prostate biopsy: A qualitative study
od: Avery, K, i wsp.
Wydane: (2007)

Seasonal variation in prostate-specific antigen levels: A large cross-sectional study of men in the UK
od: Down, L, i wsp.
Wydane: (2011)

Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?
od: Avery, K, i wsp.
Wydane: (2008)

Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?
od: Macefield, R, i wsp.
Wydane: (2009)

Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK.
od: Down, L, i wsp.
Wydane: (2011)

Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.
od: Lane, J, i wsp.
Wydane: (2010)

Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer
od: Hamdy, FC, i wsp.
Wydane: (2023)

ProDiet: A phase II randomized placebo-controlled trial of green tea catechins and lycopene in men at increased risk of prostate cancer
od: Lane, JA, i wsp.
Wydane: (2018)

Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: The CAP randomized clinical trial
od: Martin, RM, i wsp.
Wydane: (2018)

ASSOCIATIONS OF SEXUAL DYSFUNCTION WITH LOCALIZED AND ADVANCED PROSTATE CANCER: A CASE-CONTROL STUDY NESTED WITHIN THE UK POPULATION-BASED PROTECT (PROSTATE TESTING FOR CANCER AND TREATMENT) STUDY
od: Collin, S, i wsp.
Wydane: (2009)

Ethics of clinical trials from bayesian perspective: randomisation to clinical trials may solve dilemma of treatment choice in prostate cancer.
od: Hamdy, F, i wsp.
Wydane: (2003)

The protect trial - Evaluating the effectiveness of treatments for clinically localised prostate cancer and associated molecular and genetic epidemiology studies
od: Lane, J, i wsp.
Wydane: (2007)

Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer
od: Donovan, J, i wsp.
Wydane: (2016)

Understanding and improving recruitment to randomised controlled trials: Qualitative research approaches.
od: Elliott, D, i wsp.
Wydane: (2017)

A review of reporting of participant recruitment and retention in RCTs in six major journals
od: Tomlin Zelda, i wsp.
Wydane: (2009-07-01)

Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the protecT randomised controlled trial according to treatment received
od: Neal, D, i wsp.
Wydane: (2019)

Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes
od: Simpkin, A, i wsp.
Wydane: (2013)

Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
od: Rosario, D, i wsp.
Wydane: (2008)

Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
od: Collin, S, i wsp.
Wydane: (2009)

Informed consent in randomised controlled trials: development and preliminary evaluation of a measure of Participatory and Informed Consent (PIC)
od: Julia Wade, i wsp.
Wydane: (2017-07-01)

Polygenic prediction of occupational status GWAS elucidates genetic and environmental interplay in intergenerational transmission, careers and health in UK Biobank
od: Akimova, ET, i wsp.
Wydane: (2024)

Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities.
od: Williams, N, i wsp.
Wydane: (2011)